Consensus Faeth Therapeutics, Inc.

Stocks

FTH

US81728A2078

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-22 EDT			5-day change	1st Jan Change
33.40 ^USD	+0.33%		-5.57%	+213.03%

09-20	Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to S&P Biotechnology Select Industry Index	CI
09-17	Faeth Therapeutics, Inc. Announces Appointment of Karen Vousden to Board of Directors and Compensation Committee Member, Effective September 11, 2026	CI

Evolution of the Average Target: Faeth Therapeutics, Inc.

Evolution of the Target Price: Faeth Therapeutics, Inc.

Changes in Analyst Recommendations: Faeth Therapeutics, Inc.

c8983c682c8fe.rG7YQ-rdTKU3APWzIpuNmObf43Ns7TPnTQRyh5elgBs.lACiFNykedQGabKLcvPerZGApB4CnkbeHkAr69Pg5nOBGbILp4V06UBxkg~ac6ab4e158e2bc04479de607858a24ac

Analysts' recommendations: Faeth Therapeutics, Inc.

09-16	Guggenheim Initiates Faeth Therapeutics at Buy With $70 Price Target	MT
09-09	TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating	MT
08-21	Needham Initiates Faeth Therapeutics at Buy With $56 Price Target	MT
07-31	Raymond James Initiates Faeth Therapeutics at Outperform	MT
07-28	Faeth Therapeutics' Experimental Cancer Drug Piktor Has Upside Potential, Oppenheimer Says	MT
07-28	Oppenheimer Initiates Faeth Therapeutics at Outperform	MT
06-26	Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target	MT
06-22	HC Wainwright Initiates Faeth Therapeutics at Buy With $60 Price Target	MT
06-11	BTIG Research Initiates Coverage on Sensei Biotherapeutics With Buy Rating, $55 Price Target	MT
05-29	Cantor Fitzgerald Initiates Sensei Biotherapeutics at Overweight	MT
04-20	Leerink Partners Initiates Coverage on Sensei Biotherapeutics With Outperform Rating, $50 PT	MT
25-03-28	Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating	MT
24-05-14	Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target	MT
23-12-04	HC Wainwright Initiates Sensei Biotherapeutics With Buy Rating, Price Target is $4	MT
22-12-13	Citigroup Initiates Sensei Biotherapeutics at Buy Rating	MT
22-11-10	Sensei Biotherapeutics : Mixed Q3; but cash cushion remains intact
22-10-03	Oppenheimer Upgrades Sensei Biotherapeutics to Outperform From Perform; Price Target is $5	MT
22-08-10	Sensei Biotherapeutics : Decent Q2; aided further by improving sentiment for Biotechs
22-05-17	Factoring in recent change of priorities (Sensei Biotherapeutics)	AL
22-05-13	Sensei Biotherapeutics : Investment continues amidst various market challenges
22-05-13	Investment continues amidst various market challenges (Sensei Biotherapeutics)	AL
22-04-01	Berenberg Bank Adjusts Sensei Biotherapeutics Price Target to $6 From $12, Maintains Hold Rating	MT
22-03-14	Sensei Biotherapeutics : Market sentiment continues to outweigh on-track clinical progress
22-03-10	Piper Sandler Adjusts Sensei Biotherapeutics' Price Target to $10 from $12, Keeps Overweight Rating	MT
21-08-09	Sensei Biotherapeutics : After SNS-301 setback, focus shifts to other programmes

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	FAETH THERAPEUTICS, INC.					+69.66%
	WUXI APPTEC CO., LTD.					+11.45%
	ARGENX SE					+20.14%
	WUXI BIOLOGICS (CAYMAN) INC.					+10.58%
	INSMED INCORPORATED					+65.16%
	BIONTECH SE					+17.73%
	GENMAB A/S					+1.06%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.41%
	PHARMAESSENTIA CORPORATION					+20.45%
	EXELIXIS, INC.					-7.67%
	Average					+23.50%
	Weighted average by Cap.					+18.58%